Chan, Rory
Lipworth, Brian
Article History
Received: 16 March 2022
Accepted: 17 May 2022
First Online: 3 June 2022
Declarations
:
: Dr. Lipworth reports non-financial support (equipment) from GSK; equipment, consulting and talks from Thorasys; consulting, advisory board and talks for Circassia; grants, personal fees (consulting, talks and advisory board), other support (attending ATS and ERS) from AstraZeneca, grants, personal fees (consulting, talks, advisory board), other support (attending ERS) from Teva, grants, personal fees (consulting talks and advisory board) and other support from Chiesi, grants, personal fees (consulting, advisory board and talks) from Sanofi, personal fees (consulting, talks and advisory board) from Circassia; in relation to the submitted work; personal fees (consulting) from Lupin, personal fees (consulting and talks) from Glenmark, personal fees (consulting) from Vectura, personal fees (consulting) from Dr Reddy, personal fees (consulting) from Sandoz; grants, personal fees (consulting, talks, advisory board), other support (attending BTS) from Boehringer Ingelheim, grants and personal fees (advisory board and talks) from Mylan outside of the submitted work; and the son of BJL is presently an employee of AstraZeneca. Dr. Chan has no relevant conflicts of interest.